MX2021015724A - Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos. - Google Patents

Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.

Info

Publication number
MX2021015724A
MX2021015724A MX2021015724A MX2021015724A MX2021015724A MX 2021015724 A MX2021015724 A MX 2021015724A MX 2021015724 A MX2021015724 A MX 2021015724A MX 2021015724 A MX2021015724 A MX 2021015724A MX 2021015724 A MX2021015724 A MX 2021015724A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
myeloid leukemia
acute myeloid
treating acute
chemotherapeutic agents
Prior art date
Application number
MX2021015724A
Other languages
English (en)
Inventor
In Hwan Bae
Young Gil Ahn
Ji Young Song
Jae Yul Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2021015724A publication Critical patent/MX2021015724A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan: una composición farmacéutica para tratar la leucemia mieloide (AML) y un método para tratar la leucemia mieloide aguda usando esta, donde la composición farmacéutica comprende una combinación terapéuticamente eficaz de un inhibidor de la tirosina quinada 3 similar a Fms (FLT3) o una sal o solvato farmacéuticamente aceptable de este, y un agente quimioterapéutico o sal o solvato.
MX2021015724A 2019-06-27 2020-06-25 Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos. MX2021015724A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190077302 2019-06-27
PCT/KR2020/008258 WO2020262974A1 (ko) 2019-06-27 2020-06-25 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2021015724A true MX2021015724A (es) 2022-05-16

Family

ID=74060307

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015724A MX2021015724A (es) 2019-06-27 2020-06-25 Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.

Country Status (11)

Country Link
US (1) US20220354842A1 (es)
EP (1) EP3991733A4 (es)
JP (1) JP2022538817A (es)
KR (1) KR20210002015A (es)
CN (1) CN114650823A (es)
AU (1) AU2020308814A1 (es)
CA (1) CA3145391A1 (es)
EA (1) EA202290154A1 (es)
IL (1) IL289366A (es)
MX (1) MX2021015724A (es)
WO (1) WO2020262974A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305178A (en) * 2021-02-26 2023-10-01 Tyra Biosciences Inc Aminopyrimidine compounds and methods of using them
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008111441A1 (ja) * 2007-03-05 2010-06-24 協和発酵キリン株式会社 医薬組成物
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
BRPI1013698A2 (pt) * 2009-03-23 2016-04-26 Ambit Biosciences Corp métodos para tratamento com o uso de terapia de combinação
EP2454257B1 (en) * 2009-07-15 2013-08-21 AbbVie Inc. Pyrrolopyridine inhibitors of kinases
JP2019512495A (ja) 2016-03-29 2019-05-16 アステラス製薬株式会社 急性骨髄性白血病の治療のための併用療法
KR102175710B1 (ko) 2017-01-23 2020-11-06 주식회사 엘지화학 폴리아릴렌 설파이드 수지 조성물
PT3514153T (pt) 2017-01-26 2021-09-22 Hanmi Pharm Ind Co Ltd Composto de pirimidina e utilização farmacêutica do mesmo
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
SG11202108867VA (en) * 2019-02-22 2021-09-29 Hanmi Pharmaceutical Co Ltd Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia

Also Published As

Publication number Publication date
EP3991733A4 (en) 2023-07-05
JP2022538817A (ja) 2022-09-06
WO2020262974A1 (ko) 2020-12-30
IL289366A (en) 2022-02-01
CN114650823A (zh) 2022-06-21
KR20210002015A (ko) 2021-01-06
US20220354842A1 (en) 2022-11-10
CA3145391A1 (en) 2020-12-30
EA202290154A1 (ru) 2022-03-29
EP3991733A1 (en) 2022-05-04
AU2020308814A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MX2021015724A (es) Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
CR20230066A (es) Agonistas del glp-1 heterocíclicos
MX2021012549A (es) Derivados de tetrahidro-1h-ciclopenta[cd]indeno como inhibidores del factor inducible por hipoxia-2(alfa).
MX2021001952A (es) Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met.
MX2020007947A (es) Inhibidores de erbb/btk.
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
SG148202A1 (en) Quinazolinone compounds as anticancer agents
MX2022009524A (es) Agonistas heterociclicos de glp-1.
MX2023008954A (es) Inhibidores de los receptores erbb.
MX2021009444A (es) Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MXPA04005425A (es) Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
CA3156484A1 (en) PHARMACEUTICAL MEDICINAL PRODUCT CONTAINING A HETEROCYCLIDENE ACETAMIDE DERIVATIVE
GEP20237476B (en) N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
MX2023007446A (es) Compuesto heterociclico aromatico, composicion farmaceutica y uso de estos.
MX2021007247A (es) Derivados de rapamicina.
EA202191984A1 (ru) Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
PH12020551772A1 (en) Oxo-substituted compound
MX2021009206A (es) Terapias contra el cancer.
TW200517146A (en) Novel composition
MX2022011711A (es) Compuesto de oxofenilarsina deuterada y uso del mismo.